Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H10N2O |
InChIKeyWZBDRAAGHRCRKM-UHFFFAOYSA-N |
CAS Registry2089-82-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 11 Oct 2017 | |
| Neoplasms | Preclinical | United States | 11 Oct 2017 |





